Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is a technology company with a positive outlook, as evidenced by the recent Los Reyes PEA, which outlines a NPV of US$1,491M, IRR of 37.3%, and payback of 1.9 years on upfront capital of US$515M. The company anticipates LOM production to average 134 koz AuEq per year over 14.4 years, with a significant increase in the first 11 years and a low LOM AISC of US$1,617/oz AuEq. Furthermore, the company has a strong financial outlook, with plans for internal funding from Morelos FCF for future growth and a conference call scheduled to discuss the positive PEA results.

Bears say

10x Genomics is currently facing challenges in terms of its valuation and financials, with a current valuation at 7.7x 2028 estimated enterprise value/revenue and a price-to-naval value of 0.51x. Additionally, the company has incurred significant debt of $84 million, further impacting its outlook. These factors, coupled with the company's reliance on development-stage assets, contribute to a negative outlook on its stock.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.